Skip to main content

Table 2 Clinical and lab features of untreated TA patients with positive or negative ASO

From: Elevated antistreptolysin O titer is closely related to cardiac mitral insufficiency in untreated patients with Takayasu arteritis

 ASO positive
n = 13
ASO negative
n = 61
P-Value
Female, n(%)11 (84.6)49 (78.7)0.720
Age of onset (year)29.5 ± 10.033.5 ± 12.50.281
Disease duration (month)6.0 (1.0, 102.0)48.0 (12.0, 168.0)0.081
BMI (kg/m2)23.3 ± 3.522.8 ± 3.50.641
Arteriosclerosis, n(%)3 (23.1)30 (49.2)0.086
Hypertension, n(%)5 (38.5)13 (21.3)0.191
T2DM, n(%)0 (0.0)4 (6.6)0.342
Smoker, n(%)2 (15.4)11 (18.0)0.820
Heart failure, n(%)4 (30.8)9 (14.8)0.168
AF, n(%)0 (0.0)0 (0.0)
Aneurysms, n(%)3 (23.1)13 (21.3)0.966
Dizziness, n(%)7 (53.9)27 (44.3)0.529
Headache, n(%)2 (15.4)11 (18.0)0.820
Asymmetry in BP, n(%)6 (46.2)23 (37.7)0.571
Pulseless, n(%)4 (30.8)13 (21.3)0.462
Chest tightness, n(%)5 (38.5)17 (27.9)0.448
Chest pain, n(%)2 (15.4)15 (24.6)0.474
Palpitations, n(%)3 (23.1)4 (6.6)0.065
Carotidynia, n(%)1 (7.7)4 (6.6)0.882
Erythema nodosum, n(%)1 (7.7)1 (1.6)0.222
Blurred vision, n(%)0 (0.0)4 (6.6)0.342
Fever, n(%)3 (23.1)9 (14.8)0.460
Fatigue, n(%)4 (30.8)14 (23.0)0.551
Weight loss, n(%)2 (15.4)3 (4.9)0.172
Numano Type
 I3 (23.1)16 (26.2)0.086
 IIa1 (7.7)3 (7.7)0.688
 IIb3 (23.1)9 (14.8)0.460
 III1 (7.7)4 (6.6)0.882
 IV1 (7.7)1 (1.6)0.222
 V4 (30.8)25 (41.0)0.493
 P+3 (23.1)7 (11.5)0.267
 C+1 (7.7)14 (23.0)0.214
  1. Note: BMI Body mass index; T2DM type 2 diabetes mellitus; AF atrial fibrillation; P+ pulmonary artery involvement; C+ coronary artery involvement